An exploratory phase II study of the combination of a tyrosine kinase inhibitor (STI571) [imatinib] and a pegylated human recombinant interferon alfa2b (PEGINTRON) [peginterferon alfa-2b] in the treatment of chronic myeloid leukemia in chronic phase.
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2009
At a glance
- Drugs Imatinib; Peginterferon alfa-2b
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 24 Aug 2007 New trial record.